CR20170218A - Composiciones anticancerígenas - Google Patents

Composiciones anticancerígenas

Info

Publication number
CR20170218A
CR20170218A CR20170218A CR20170218A CR20170218A CR 20170218 A CR20170218 A CR 20170218A CR 20170218 A CR20170218 A CR 20170218A CR 20170218 A CR20170218 A CR 20170218A CR 20170218 A CR20170218 A CR 20170218A
Authority
CR
Costa Rica
Prior art keywords
prostate cancer
castration
resistant
metastases
cancer
Prior art date
Application number
CR20170218A
Other languages
English (en)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006907&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170218(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CR20170218A publication Critical patent/CR20170218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de ARN-509 que pueden ser administradas a un mamífero, particularmente a un ser humano, que padece de una enfermedad o afección relacionada con el receptor androgénico (RA), particularmente cáncer, más particularmente cáncer de próstata, incluidos, a título meramente enunciativo, cáncer de próstata resistente a la castración, cáncer de próstata con metástasis resistente a la castración, cáncer de próstata con metástasis resistente a la castración sin tratamiento previo con quimioterapia, cáncer de próstata sensible a las hormonas con recidiva bioquímica o cáncer de próstata no metastásico resistente a la castración y de alto riesgo
CR20170218A 2014-12-05 2015-12-03 Composiciones anticancerígenas CR20170218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196605 2014-12-05
PCT/US2015/063671 WO2016090105A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
CR20170218A true CR20170218A (es) 2017-08-30

Family

ID=52006907

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170218A CR20170218A (es) 2014-12-05 2015-12-03 Composiciones anticancerígenas

Country Status (33)

Country Link
US (3) US10285948B2 (es)
EP (2) EP3226843B1 (es)
JP (1) JP6830892B2 (es)
KR (1) KR102387089B1 (es)
CN (1) CN106999432A (es)
AR (1) AR102925A1 (es)
AU (1) AU2015358497B2 (es)
CA (1) CA2969675C (es)
CL (1) CL2017001373A1 (es)
CO (1) CO2017005574A2 (es)
CR (1) CR20170218A (es)
CY (1) CY1124504T1 (es)
DK (1) DK3226843T3 (es)
EA (1) EA201791251A1 (es)
ES (1) ES2883187T3 (es)
HR (1) HRP20211140T1 (es)
HU (1) HUE054935T2 (es)
IL (1) IL252325A0 (es)
LT (1) LT3226843T (es)
MA (1) MA41111B1 (es)
MD (1) MD3226843T2 (es)
MX (1) MX2017007206A (es)
MY (1) MY192931A (es)
NI (1) NI201700068A (es)
PH (1) PH12017500979A1 (es)
PL (1) PL3226843T3 (es)
PT (1) PT3226843T (es)
RS (1) RS62421B1 (es)
SG (1) SG11201704386VA (es)
SI (1) SI3226843T1 (es)
TW (1) TWI709403B (es)
UA (1) UA123538C2 (es)
WO (1) WO2016090105A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
EP3226843B1 (en) * 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
EP3918607A1 (en) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Methods of treating prostate cancer based on molecular subtypes
AU2020215176A1 (en) 2019-01-30 2021-08-05 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療***癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249911A (en) 1992-03-31 1996-06-25 British Tech Group 17-(3-pyridyl) substituted steroids and use in pharmaceutical compositions
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CA2400845A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
DE60206889T2 (de) 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
IL157955A0 (en) 2001-04-02 2004-03-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
MXPA03011933A (es) 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
JPWO2003077827A1 (ja) 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
WO2005055987A1 (en) 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER
EP2656842B1 (en) 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
SG173178A1 (en) * 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
PT3124481T (pt) 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CA2839301C (en) 2011-06-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
TWI532732B (zh) 2012-06-07 2016-05-11 亞拉岡製藥公司 雄性激素受體調節劑之晶型
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
WO2014031422A1 (en) 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel hydroxyalkyl methyl cellulose acetate succinates
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森***医疗有限责任公司 恩杂鲁胺制剂
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
EA030128B1 (ru) * 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
AU2014210103B2 (en) 2013-01-22 2018-09-06 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
KR102121404B1 (ko) 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
WO2015116696A1 (en) * 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EA201891397A1 (ru) * 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
JP6306201B2 (ja) 2014-02-06 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インターロイキン−２融合タンパク質及びその使用
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
EP3226843B1 (en) * 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
US20190216829A1 (en) * 2016-06-03 2019-07-18 Aragon Pharmaceuticals, Inc. Anticancer Compositions

Also Published As

Publication number Publication date
EP3226843B1 (en) 2021-05-26
CA2969675C (en) 2023-06-06
MA41111B1 (fr) 2021-09-30
MY192931A (en) 2022-09-15
WO2016090105A1 (en) 2016-06-09
PH12017500979A1 (en) 2017-11-27
TWI709403B (zh) 2020-11-11
ES2883187T3 (es) 2021-12-07
BR112017011726A2 (pt) 2017-12-26
UA123538C2 (uk) 2021-04-21
DK3226843T3 (da) 2021-08-16
PT3226843T (pt) 2021-07-07
US20210308060A1 (en) 2021-10-07
LT3226843T (lt) 2021-08-10
SG11201704386VA (en) 2017-06-29
JP2017536407A (ja) 2017-12-07
KR102387089B1 (ko) 2022-04-14
SI3226843T1 (sl) 2021-11-30
KR20170086658A (ko) 2017-07-26
CL2017001373A1 (es) 2018-01-05
PL3226843T3 (pl) 2021-12-13
EA201791251A1 (ru) 2017-11-30
RS62421B1 (sr) 2021-10-29
IL252325A0 (en) 2017-07-31
NI201700068A (es) 2017-09-11
MD3226843T2 (ro) 2021-10-31
JP6830892B2 (ja) 2021-02-17
US11224575B2 (en) 2022-01-18
AU2015358497A1 (en) 2017-06-08
CO2017005574A2 (es) 2017-09-29
HUE054935T2 (hu) 2021-10-28
MX2017007206A (es) 2018-01-30
AR102925A1 (es) 2017-04-05
CY1124504T1 (el) 2022-07-22
CN106999432A (zh) 2017-08-01
TW201636019A (zh) 2016-10-16
US11911511B2 (en) 2024-02-27
US20170360713A1 (en) 2017-12-21
EP3925598A1 (en) 2021-12-22
AU2015358497B2 (en) 2021-04-29
US10285948B2 (en) 2019-05-14
US20190209477A1 (en) 2019-07-11
HRP20211140T1 (hr) 2021-10-15
EP3226843A1 (en) 2017-10-11
CA2969675A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CR20170216A (es) Composiciones anticancerígenas
CR20170218A (es) Composiciones anticancerígenas
CR20170217A (es) Composiciones anticancerígenas
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
NZ742351A (en) Inhibitors of ret
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112018070361A2 (pt) redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
NZ737399A (en) Ccr2 modulators
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
EA201792520A3 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.